身体功能评分最低的人在提尔泽帕提德治疗后表现出最大的改善
Xuan Li1, Dachuang Cao1, Helene Sapin1
1Eli Lilly and Company, Indianapolis, Indiana, USA.
Obesity (Silver Spring, Md.)
|November 4, 2025
概括
较低的基线身体功能 (PF) 与更多的肥胖并发症有关. 蒂尔泽帕提德显著改善PF,可能通过体重减轻依赖和独立的途径,特别是在那些初始PF较差的人群中.
科学领域:
- 代谢障碍和肥胖症研究研究
- 临床试验分析临床试验分析
- 针对肥胖的药理干预措施
背景情况:
- 与肥胖相关的并发症 (ORCs) 显著影响患者的健康.
- 基线身体功能 (PF) 是评估肥胖结果的关键因素.
- 了解新型肥胖治疗的机制至关重要.
研究的目的:
- 分析基线物理功能 (PF) 和与肥胖有关的并发症 (ORCs) 之间的关联.
- 为了评估蒂尔泽帕提德在改善不同基线PF水平的PF方面的疗效.
- 调查蒂尔泽帕提德对PF的影响背后的机制.
主要方法:
- 对SURMOUNT-1,SURMOUNT-3和SURMOUNT-4试验的后期分析.
- 参与者根据基线SF-36v2 PF分数被分为四分之一.
- ANCOVA用于有效性测量和PF变化; 皮尔森对减肥和PF改善的相关性.
主要成果:
- 较低的基线PF与较高的ORCs患病率相关.
- 蒂尔泽帕提德在所有PF四分位数中表现出显著的体重减轻.
- 在具有较低基线PF的参与者中观察到与tirepatide一起更大的PF改善.
结论:
- 降低基线PF与ORCs增加有关.
- 蒂尔泽帕提德有效地降低体重并改善PF,无论基线功能如何.
- 蒂尔泽帕提德的PF改善可能涉及体重减轻依赖和独立的机制.
更多相关视频
08:48Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
Published on: January 29, 2016
17.2K
12:59Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
13.0K
相关概念视频
01:24Parkinson's Disease: Treatment
963
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
963
01:26Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311